Animal & Veterinary
Consent Decree Entered In Drug Tissue Residue Case
May 19, 1999
On March 23, 1999, the U.S. District Court for the Central District of California accepted and entered a Consent Decree of Permanent Injunction between the United States and Ivan A. Wood, doing business as Woodcrest Dairy. Woodcrest Dairy is a livestock producer located in Ontario, California.
An FDA investigation of Woodcrest Dairy’s operations revealed that since 1993, Mr. Wood caused numerous illegal drug tissue residues in livestock intended for food in spite of multiple written notifications from FDA, the U.S. Department of Agriculture (USDA), and the California Department of Food and Agriculture warning him of previous violations and the need to improve poor husbandry practices in his business.
Under the terms of the Consent Decree, Mr. Wood voluntarily agreed to be permanently restrained and enjoined from directly or indirectly introducing or causing to be introduced into interstate commerce any livestock or their tissues until the corrective actions enumerated in the decree are established and implemented. Some of these corrective actions are:
- the implementation of adequate recordkeeping practices documenting the administration of drugs and withdrawal periods in livestock;
- the establishment of a drug inventory and accountability system that will help to prevent future sales or distribution of animals that may contain illegal drug tissue residues;
- the presence of a system that will prevent the administration of drug in excess of approved dosage, sale of animals before drug withdrawal period, storage of expired drugs and extra-label use of drugs;
- the implementation of a system ensuring the segregation between medicated and unmedicated animals.
In addition, Mr. Wood cannot cause the adulteration of food or drugs at any time in the future. Failure to comply with the terms of this Consent Decree may result in civil or criminal penalties.
The FDA’s Los Angeles District Office conducted the investigation that lead to this Consent Decree. The FDA/CVM’s Division of Compliance, the FDA’s Office of the Chief Counsel, and the U.S. Department of Justice’s Office of Consumer Litigation were responsible for the case processing and legal procedures.